May 6, 2009
Anthera's Varespladib Meets Primary Endpoint In Phase 2 Francis Trial For The Treatment Of Acute Coronary Syndrome ...read more
March 24, 2009Following Encouraging Results Anthera To Continue Impacts Trial For The Prevention Of Acute Chest Syndrome In Patients With Sickle Cell Disease ...read more
January 12, 2009Anthera Announces Enrollment Of 500th Patient In Francis Trial Of A-002 For The Treatment Of Cardiovascular Disease ...read more
November 11, 2008Anthera,s Varespladib Demonstrates Significant Anti-Inflammatory Effect And LDL Reduction In Patients With Coronary Heart Disease ...read more
August 25, 2008Anthera Pharmaceuticals Advances Global Development Strategy For Varespladib In Patients With Acute Coronary Syndrome With The Initiation Of Francis Trial ...read more
August 13, 2008Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman ...read more
April 17, 2008Anthera presents data on Varespladib at ATVB meeting ...read more
April 16, 2008DSMB supports continuation of Anthera phase II IMPACTS trial for the prevention of acute chest syndrome in patients with sickle cell disease ...read more
February 7‚ 2008Data From Anthera's PLASMA Trial to be Presented as Late Breaker at American College of Cardiology Scientific Sessions ...read more
January 31‚ 2008Anthera enters into manufacturing agreements for varespladib in preparation for pivotal Phase III trials ...read more
January 15‚ 2008Anthera Announces Preliminary Positive Results from Once-Daily A-002 Phase II Cardiovascular Trial ...read more
January 8‚ 2008Anthera Pharmaceuticals acquires the worldwide rights to a BAFF inhibitor for the treatment of lupus and other autoimmune diseases. ...read more
December 18‚ 2007Anthera,s A-001 Receives orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease ...read more
December 06‚ 2007Anthera Pharmaceuticals names Christopher P. Lowe Chief Financial Officer ...read more
October 30‚ 2007Anthera Pharmaceuticals, Inc. appoints Donald Santel to Board of Directors ...read more
October 24‚ 2007Anthera announces Positive Phase II clinical results from A-002 cardiovascular disease trial ...read more
October 3‚ 2007Anthera announces completion of enrollment and dosing in Phase II trial of A-002 for the treatment of cardiovascular disease trial ...read more
July 2‚ 2007Anthera Completes Enrollment of "PLASMA" Trial with A-002 and Announces Initiation of New Investigator Study ...read more
April 13‚ 2007First Patient Enrolled In Phase 2 "PLASMA" Trial with A-002 for Patients with Coronary Atherosclerosis ...read more
March 20‚ 2007Anthera Pharmaceuticals‚ Inc. Announces Appointment of Dr. James Pennington as Executive Vice President & Chief Medical Officer ...read more
March 8‚ 2007Anthera Pharmaceuticals‚ Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs ...read more
February 13‚ 2007Anthera Pharmaceuticals‚ Inc. Announces Formation of Clinical Advisory Board for CARDIOVASCULAR Program ...read more
February 7‚ 2007Dr. David D. Waters Joins Anthera Pharmaceuticals as Cardiovascular Research Fellow ...read more
January 9‚ 2007Anthera Receives IND Approval from FDA to begin phase 2 “IMPACTS” trial with a-001 for prevention of acute chest syndrome in patients with sickle cell disease ...read more
January 4‚ 2007Anthera Receives FDA Approval to begin phase 2 “PLASMA” trial with a-002 For patients with coronary atherosclerosis ...read more
Dec 10‚ 2006Anthera Employee Keiko Mitsunobu Finishes Honolulu Marathon In Successful Effort To Raise Money For Children's Hospital Oakland Research Institute ...read more
September 13‚ 2006Anthera Pharmaceuticals Secures $36M Venture Financing To Initiate Clinical Programs ...read more
September 06‚ 2006Anthera Licenses Portfolio of Anti–Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd. ...read more
November 17‚ 2005Anthera Pharmaceuticals Appoints David E. Thompson To Board Of Directors ...read more
April 20‚ 2005Anthera Pharmaceuticals Launches With A Proven Leadership Team And Significant Series A Funding ...read more
